Brought to you by 
Vanderbilt licenses mGluR4 modulators for Parkinson’s to BMS
02 Oct 2012
Executive Summary
Vanderbilt University’s Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has licensed Bristol-Myers Squibb Co. rights to develop and market its positive allosteric modulators of the metabotropic glutamate receptor 4 (mGluR4) for Parkinson’s disease (PD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com